Adalimumab (HUMIRA, Abbott Laboratories) is a new fully human TNF-alpha monoclonal antibody recently approved for the treatment of rheumatoid arthritis and undergoing trials for use in treating other conditions, including psoriasis and psoriatic arthritis. This article reviews its mechanisms of action, clinical trial results, and related discussion.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Assessing early therapeutic drug monitoring of adalimumab as a predictor of treatment efficacy and immunogenicity in rheumatic diseases: "early therapeutic drug monitoring of adalimumab".
Clin Rheumatol
January 2025
Department of Public Health, University of Murcia, Campus de Ciencias de la Salud, Murcia, 30120, Spain.
Introduction: Therapeutic drug monitoring (TDM) in inflammatory rheumatic diseases (RMDs) is gaining interest. However, there are unresolved questions about the best practices for implementing TDM effectively in clinical settings.
Objective: The primary objective of this study was to evaluate whether early TDM of adalimumab predicts drug survival at 52 weeks in patients with RMDs.
"I don't worry about going outside anymore": a patient's journey with recalcitrant lupus pernio, responsive to adalimumab".
Clin Exp Dermatol
January 2025
Department of Dermatology, Our Lady of Lourdes Hospital, Drogheda, Louth, Ireland.
Correction: Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study.
Drugs Real World Outcomes
January 2025
Biogen IDEC, Clinical Research, Biosimilars, Maidenhead, UK.
Cross-sectional patient survey of biological medicine users in Finland to investigate the types of guidance needed by patients in order to carry out their treatment successfully.
BMJ Open
January 2025
Oriola Finland Oy, Espoo, Uusimaa, Finland
Background: The use of new biological medicines as standard treatment is expected to increase substantially and cover new therapeutic indications in the near future. Interchange of biological medicines in pharmacies increases the need for patient guidance.
Objectives: The study aims to gain a patient perspective on biological medicine users' needs and wishes regarding patient guidance by exploring what kind of information patients wish to receive and to further investigate the potential differences in needs between originator biological medicine users and biosimilar users.
Tumor necrosis factor-alpha (TNF-α) inhibitors are commonly used for management of various autoimmune disorders but can rarely cause isolated cutaneous lupus. This report presents two cases of cutaneous lupus erythematosus (LE) in women aged 38 and 61 after adalimumab treatment for psoriasis highlighting the importance of recognizing these paradoxical reactions for timely management.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!